Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | AZD0901 |
Synonyms | |
Therapy Description |
Limited information is currently available on AZD0901, a putative antibody-drug conjugate (ADC) targeting CLDN18.2 (Jan 2024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD0901 | AZD-0901|AZD 0901 | CLDN18.2 Antibody 18 | Limited information is currently available on AZD0901, a putative antibody-drug conjugate (ADC) targeting CLDN18.2 (Jan 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06346392 | Phase III | Rivoceranib Trifluridine-tipiracil hydrochloride Paclitaxel + Ramucirumab Docetaxel Paclitaxel Irinotecan AZD0901 | AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | 7 |
NCT06219941 | Phase II | AZD0901 + Irinotecan AZD0901 + Liposomal irinotecan AZD0901 + Leucovorin AZD0901 + Fluorouracil AZD0901 + Gemcitabine AZD0901 | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | Recruiting | USA | GBR | ESP | CAN | AUS | 7 |